Drug Profile
Research programme: PAR2-neutralising monoclonal antibodies - Nxera Pharma
Alternative Names: Anti-PAR2 mAb; PAR2 mAb - Nxera PharmaLatest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Heptares Therapeutics; MorphoSys
- Developer MorphoSys; Nxera Pharma
- Class Anti-inflammatories; Antineoplastics; Immunotherapies; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies
- Mechanism of Action PAR 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Atopic dermatitis
- No development reported Cancer; Inflammation; Metabolic disorders; Neurodegenerative disorders